APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Gene Cell Therapy CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Gene Cell Therapy CDMO Market Analysis and Forecast 2026-2032

Report ID 17414843024 January 2026203 pages

Choose your research edition.

Industry ResearchGene Cell Therapy CDMO Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene Cell Therapy CDMO Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Gene Cell Therapy CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene Cell Therapy CDMO Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Gene Cell Therapy CDMO Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Gene Cell Therapy CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Gene Cell Therapy CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Gene Cell Therapy CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Gene Cell Therapy CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Gene Cell Therapy CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Gene Cell Therapy CDMO include Catalent, Lonza, Charles River, Oxford Biomedica, Novartis, OBiO, GenScript, Pharmaron and Porton, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Gene Cell Therapy CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Gene Cell Therapy CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Gene Cell Therapy CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gene Cell Therapy CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Gene Cell Therapy CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Gene Cell Therapy CDMO revenue, projected growth trends, production technology, application and end-user industry.

Gene Cell Therapy CDMO Segment by Company

Catalent

Lonza

Charles River

Oxford Biomedica

Novartis

OBiO

GenScript

Pharmaron

Porton

Resilience

SK Pharmteco

Forge Biologics

Andelyn Biosciences

Roslin CT

eXmoor Pharma

Advanced Therapies

Catalent Biologics

Patheon Pharma Services

Gene Cell Therapy CDMO Segment by Type

Immune Cells

Stem Cell

Viral Vector

Plasmid DNA

Gene Cell Therapy CDMO Segment by Application

Pharmaceutical and Biotechnology Companies

Research and Academic Institutions

Hospital

Others

Gene Cell Therapy CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Cell Therapy CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene Cell Therapy CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Cell Therapy CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Gene Cell Therapy CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Gene Cell Therapy CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gene Cell Therapy CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gene Cell Therapy CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Immune Cells Major Player Table 3. Stem Cell Major Player Table 4. Viral Vector Major Player Table 5. Plasmid DNA Major Player Table 6. Global Gene Cell Therapy CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Pharmaceutical and Biotechnology Companies Major Player Table 8. Research and Academic Institutions Major Player Table 9. Hospital Major Player Table 10. Others Major Player Table 11. Gene Cell Therapy CDMO Industry Trends Table 12. Gene Cell Therapy CDMO Industry Drivers Table 13. Gene Cell Therapy CDMO Industry Opportunities and Challenges Table 14. Gene Cell Therapy CDMO Industry Restraints Table 15. Global Gene Cell Therapy CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Gene Cell Therapy CDMO Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Gene Cell Therapy CDMO Market Share by Region (2021-2026) Table 18. Global Gene Cell Therapy CDMO Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Gene Cell Therapy CDMO Market Share by Region (2027-2032) Table 20. Global Gene Cell Therapy CDMO Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Gene Cell Therapy CDMO Revenue Market Share by Players (2021-2026) Table 22. Global Gene Cell Therapy CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Gene Cell Therapy CDMO Key Players Headquarters & Area Served Table 24. Global Gene Cell Therapy CDMO Players, Product Type & Application Table 25. Global Gene Cell Therapy CDMO Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Gene Cell Therapy CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Gene Cell Therapy CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Gene Cell Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Gene Cell Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Gene Cell Therapy CDMO Revenue Market Share by Type (2021-2026) Table 32. Global Gene Cell Therapy CDMO Revenue Market Share by Type (2027-2032) Table 33. Global Gene Cell Therapy CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Gene Cell Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Gene Cell Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Gene Cell Therapy CDMO Revenue Market Share by Application (2021-2026) Table 37. Global Gene Cell Therapy CDMO Revenue Market Share by Application (2027-2032) Table 38. Catalent Company Information Table 39. Catalent Business Overview Table 40. Catalent Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Catalent Gene Cell Therapy CDMO Product Portfolio Table 42. Catalent Recent Development Table 43. Lonza Company Information Table 44. Lonza Business Overview Table 45. Lonza Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Lonza Gene Cell Therapy CDMO Product Portfolio Table 47. Lonza Recent Development Table 48. Charles River Company Information Table 49. Charles River Business Overview Table 50. Charles River Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Charles River Gene Cell Therapy CDMO Product Portfolio Table 52. Charles River Recent Development Table 53. Oxford Biomedica Company Information Table 54. Oxford Biomedica Business Overview Table 55. Oxford Biomedica Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Oxford Biomedica Gene Cell Therapy CDMO Product Portfolio Table 57. Oxford Biomedica Recent Development Table 58. Novartis Company Information Table 59. Novartis Business Overview Table 60. Novartis Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Novartis Gene Cell Therapy CDMO Product Portfolio Table 62. Novartis Recent Development Table 63. OBiO Company Information Table 64. OBiO Business Overview Table 65. OBiO Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. OBiO Gene Cell Therapy CDMO Product Portfolio Table 67. OBiO Recent Development Table 68. GenScript Company Information Table 69. GenScript Business Overview Table 70. GenScript Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. GenScript Gene Cell Therapy CDMO Product Portfolio Table 72. GenScript Recent Development Table 73. Pharmaron Company Information Table 74. Pharmaron Business Overview Table 75. Pharmaron Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Pharmaron Gene Cell Therapy CDMO Product Portfolio Table 77. Pharmaron Recent Development Table 78. Porton Company Information Table 79. Porton Business Overview Table 80. Porton Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Porton Gene Cell Therapy CDMO Product Portfolio Table 82. Porton Recent Development Table 83. Resilience Company Information Table 84. Resilience Business Overview Table 85. Resilience Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Resilience Gene Cell Therapy CDMO Product Portfolio Table 87. Resilience Recent Development Table 88. SK Pharmteco Company Information Table 89. SK Pharmteco Business Overview Table 90. SK Pharmteco Gene Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. SK Pharmteco Gene Cell Therapy CDMO Product Portfolio Table 92. SK Pharmteco Recent Development Table 93. Forge Biologics Company Information Table 94. Forge Biologics Business Overview Table 95. Forge Biologics Gene Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Forge Biologics Gene Cell Therapy CDMO Product Portfolio Table 97. Forge Biologics Recent Development Table 98. Andelyn Biosciences Company Information Table 99. Andelyn Biosciences Business Overview Table 100. Andelyn Biosciences Gene Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Andelyn Biosciences Gene Cell Therapy CDMO Product Portfolio Table 102. Andelyn Biosciences Recent Development Table 103. Roslin CT Company Information Table 104. Roslin CT Business Overview Table 105. Roslin CT Gene Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Roslin CT Gene Cell Therapy CDMO Product Portfolio Table 107. Roslin CT Recent Development Table 108. eXmoor Pharma Company Information Table 109. eXmoor Pharma Business Overview Table 110. eXmoor Pharma Gene Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. eXmoor Pharma Gene Cell Therapy CDMO Product Portfolio Table 112. eXmoor Pharma Recent Development Table 113. Advanced Therapies Company Information Table 114. Advanced Therapies Business Overview Table 115. Advanced Therapies Gene Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Advanced Therapies Gene Cell Therapy CDMO Product Portfolio Table 117. Advanced Therapies Recent Development Table 118. Catalent Biologics Company Information Table 119. Catalent Biologics Business Overview Table 120. Catalent Biologics Gene Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Catalent Biologics Gene Cell Therapy CDMO Product Portfolio Table 122. Catalent Biologics Recent Development Table 123. Patheon Pharma Services Company Information Table 124. Patheon Pharma Services Business Overview Table 125. Patheon Pharma Services Gene Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Patheon Pharma Services Gene Cell Therapy CDMO Product Portfolio Table 127. Patheon Pharma Services Recent Development Table 128. North America Gene Cell Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 129. North America Gene Cell Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 130. North America Gene Cell Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 131. North America Gene Cell Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 132. North America Gene Cell Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. North America Gene Cell Therapy CDMO Revenue by Country (2021-2026) & (US$ Million) Table 134. North America Gene Cell Therapy CDMO Revenue by Country (US$ Million) & (2027-2032) Table 135. Europe Gene Cell Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 136. Europe Gene Cell Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 137. Europe Gene Cell Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 138. Europe Gene Cell Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 139. Europe Gene Cell Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. Europe Gene Cell Therapy CDMO Revenue by Country (2021-2026) & (US$ Million) Table 141. Europe Gene Cell Therapy CDMO Revenue by Country (US$ Million) & (2027-2032) Table 142. China Gene Cell Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 143. China Gene Cell Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 144. China Gene Cell Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 145. China Gene Cell Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 146. Asia Gene Cell Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 147. Asia Gene Cell Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 148. Asia Gene Cell Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 149. Asia Gene Cell Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 150. Asia Gene Cell Therapy CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 151. Asia Gene Cell Therapy CDMO Revenue by Region (US$ Million) & (2021-2026) Table 152. Asia Gene Cell Therapy CDMO Revenue by Region (US$ Million) & (2027-2032) Table 153. SAMEA Gene Cell Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 154. SAMEA Gene Cell Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 155. SAMEA Gene Cell Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 156. SAMEA Gene Cell Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 157. SAMEA Gene Cell Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 158. SAMEA Gene Cell Therapy CDMO Revenue by Country (2021-2026) & (US$ Million) Table 159. SAMEA Gene Cell Therapy CDMO Revenue by Country (US$ Million) & (2027-2032) Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Gene Cell Therapy CDMO Image Figure 2. Global Gene Cell Therapy CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gene Cell Therapy CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Immune Cells Image Figure 5. Stem Cell Image Figure 6. Viral Vector Image Figure 7. Plasmid DNA Image Figure 8. Global Gene Cell Therapy CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Gene Cell Therapy CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 10. Pharmaceutical and Biotechnology Companies Image Figure 11. Research and Academic Institutions Image Figure 12. Hospital Image Figure 13. Others Image Figure 14. Global Gene Cell Therapy CDMO Market Size (US$ Million) & (2021-2032) Figure 15. Global Gene Cell Therapy CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Gene Cell Therapy CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Gene Cell Therapy CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Gene Cell Therapy CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Gene Cell Therapy CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Gene Cell Therapy CDMO Revenue Market Share by Type (2021-2032) Figure 22. Global Gene Cell Therapy CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Gene Cell Therapy CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Gene Cell Therapy CDMO Revenue Market Share by Application (2021-2032) Figure 25. North America Gene Cell Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Gene Cell Therapy CDMO Revenue Share by Type (2021-2032) Figure 27. North America Gene Cell Therapy CDMO Revenue Share by Application (2021-2032) Figure 28. North America Gene Cell Therapy CDMO Revenue Share by Country (2021-2032) Figure 29. United States Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Gene Cell Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Gene Cell Therapy CDMO Revenue Share by Type (2021-2032) Figure 34. Europe Gene Cell Therapy CDMO Revenue Share by Application (2021-2032) Figure 35. Europe Gene Cell Therapy CDMO Revenue Share by Country (2021-2032) Figure 36. Germany Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Gene Cell Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Gene Cell Therapy CDMO Revenue Share by Type (2021-2032) Figure 46. China Gene Cell Therapy CDMO Revenue Share by Application (2021-2032) Figure 47. Asia Gene Cell Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Gene Cell Therapy CDMO Revenue Share by Type (2021-2032) Figure 49. Asia Gene Cell Therapy CDMO Revenue Share by Application (2021-2032) Figure 50. Asia Gene Cell Therapy CDMO Revenue Share by Region (2021-2032) Figure 51. Japan Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Gene Cell Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Gene Cell Therapy CDMO Revenue Share by Type (2021-2032) Figure 59. SAMEA Gene Cell Therapy CDMO Revenue Share by Application (2021-2032) Figure 60. SAMEA Gene Cell Therapy CDMO Revenue Share by Country (2021-2032) Figure 61. Brazil Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Gene Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Immune Cells
  • Stem Cell
  • Viral Vector
  • Plasmid DNA
Applications
  • Pharmaceutical and Biotechnology Companies
  • Research and Academic Institutions
  • Hospital
  • Others
Companies covered
  • Catalent
  • Lonza
  • Charles River
  • Oxford Biomedica
  • Novartis
  • OBiO
  • GenScript
  • Pharmaron
  • Porton
  • Resilience
  • SK Pharmteco
  • Forge Biologics
  • Andelyn Biosciences
  • Roslin CT
  • eXmoor Pharma
  • Advanced Therapies
  • Catalent Biologics
  • Patheon Pharma Services

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Gene Cell Therapy CDMO Market by Type
  3. 1.2.1 Global Gene Cell Therapy CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Immune Cells
  5. 1.2.3 Stem Cell
  6. 1.2.4 Viral Vector
  7. 1.2.5 Plasmid DNA
  8. 1.3 Gene Cell Therapy CDMO Market by Application
  9. 1.3.1 Global Gene Cell Therapy CDMO Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Pharmaceutical and Biotechnology Companies
  11. 1.3.3 Research and Academic Institutions
  12. 1.3.4 Hospital
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Gene Cell Therapy CDMO Market Dynamics
  1. 2.1 Gene Cell Therapy CDMO Industry Trends
  2. 2.2 Gene Cell Therapy CDMO Industry Drivers
  3. 2.3 Gene Cell Therapy CDMO Industry Opportunities and Challenges
  4. 2.4 Gene Cell Therapy CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Gene Cell Therapy CDMO Market Perspective (2021-2032)
  2. 3.2 Global Gene Cell Therapy CDMO Growth Trends by Region
  3. 3.2.1 Global Gene Cell Therapy CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Gene Cell Therapy CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Gene Cell Therapy CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Gene Cell Therapy CDMO Revenue by Players
  2. 4.1.1 Global Gene Cell Therapy CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Gene Cell Therapy CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Gene Cell Therapy CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Gene Cell Therapy CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Gene Cell Therapy CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Gene Cell Therapy CDMO Players, Product Type & Application
  8. 4.5 Global Gene Cell Therapy CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Gene Cell Therapy CDMO Market CR5 and HHI
  11. 4.6.3 2025 Gene Cell Therapy CDMO Tier 1, Tier 2, and Tier 3
5 Gene Cell Therapy CDMO Market Size by Type
  1. 5.1 Global Gene Cell Therapy CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Gene Cell Therapy CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Gene Cell Therapy CDMO Revenue Market Share by Type (2021-2032)
6 Gene Cell Therapy CDMO Market Size by Application
  1. 6.1 Global Gene Cell Therapy CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Gene Cell Therapy CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Gene Cell Therapy CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Catalent
  2. 7.1.1 Catalent Company Information
  3. 7.1.2 Catalent Business Overview
  4. 7.1.3 Catalent Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Catalent Gene Cell Therapy CDMO Product Portfolio
  6. 7.1.5 Catalent Recent Developments
  7. 7.2 Lonza
  8. 7.2.1 Lonza Company Information
  9. 7.2.2 Lonza Business Overview
  10. 7.2.3 Lonza Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Lonza Gene Cell Therapy CDMO Product Portfolio
  12. 7.2.5 Lonza Recent Developments
  13. 7.3 Charles River
  14. 7.3.1 Charles River Company Information
  15. 7.3.2 Charles River Business Overview
  16. 7.3.3 Charles River Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Charles River Gene Cell Therapy CDMO Product Portfolio
  18. 7.3.5 Charles River Recent Developments
  19. 7.4 Oxford Biomedica
  20. 7.4.1 Oxford Biomedica Company Information
  21. 7.4.2 Oxford Biomedica Business Overview
  22. 7.4.3 Oxford Biomedica Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Oxford Biomedica Gene Cell Therapy CDMO Product Portfolio
  24. 7.4.5 Oxford Biomedica Recent Developments
  25. 7.5 Novartis
  26. 7.5.1 Novartis Company Information
  27. 7.5.2 Novartis Business Overview
  28. 7.5.3 Novartis Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Novartis Gene Cell Therapy CDMO Product Portfolio
  30. 7.5.5 Novartis Recent Developments
  31. 7.6 OBiO
  32. 7.6.1 OBiO Company Information
  33. 7.6.2 OBiO Business Overview
  34. 7.6.3 OBiO Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 OBiO Gene Cell Therapy CDMO Product Portfolio
  36. 7.6.5 OBiO Recent Developments
  37. 7.7 GenScript
  38. 7.7.1 GenScript Company Information
  39. 7.7.2 GenScript Business Overview
  40. 7.7.3 GenScript Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GenScript Gene Cell Therapy CDMO Product Portfolio
  42. 7.7.5 GenScript Recent Developments
  43. 7.8 Pharmaron
  44. 7.8.1 Pharmaron Company Information
  45. 7.8.2 Pharmaron Business Overview
  46. 7.8.3 Pharmaron Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Pharmaron Gene Cell Therapy CDMO Product Portfolio
  48. 7.8.5 Pharmaron Recent Developments
  49. 7.9 Porton
  50. 7.9.1 Porton Company Information
  51. 7.9.2 Porton Business Overview
  52. 7.9.3 Porton Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Porton Gene Cell Therapy CDMO Product Portfolio
  54. 7.9.5 Porton Recent Developments
  55. 7.10 Resilience
  56. 7.10.1 Resilience Company Information
  57. 7.10.2 Resilience Business Overview
  58. 7.10.3 Resilience Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Resilience Gene Cell Therapy CDMO Product Portfolio
  60. 7.10.5 Resilience Recent Developments
  61. 7.11 SK Pharmteco
  62. 7.11.1 SK Pharmteco Company Information
  63. 7.11.2 SK Pharmteco Business Overview
  64. 7.11.3 SK Pharmteco Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 SK Pharmteco Gene Cell Therapy CDMO Product Portfolio
  66. 7.11.5 SK Pharmteco Recent Developments
  67. 7.12 Forge Biologics
  68. 7.12.1 Forge Biologics Company Information
  69. 7.12.2 Forge Biologics Business Overview
  70. 7.12.3 Forge Biologics Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Forge Biologics Gene Cell Therapy CDMO Product Portfolio
  72. 7.12.5 Forge Biologics Recent Developments
  73. 7.13 Andelyn Biosciences
  74. 7.13.1 Andelyn Biosciences Company Information
  75. 7.13.2 Andelyn Biosciences Business Overview
  76. 7.13.3 Andelyn Biosciences Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Andelyn Biosciences Gene Cell Therapy CDMO Product Portfolio
  78. 7.13.5 Andelyn Biosciences Recent Developments
  79. 7.14 Roslin CT
  80. 7.14.1 Roslin CT Company Information
  81. 7.14.2 Roslin CT Business Overview
  82. 7.14.3 Roslin CT Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Roslin CT Gene Cell Therapy CDMO Product Portfolio
  84. 7.14.5 Roslin CT Recent Developments
  85. 7.15 eXmoor Pharma
  86. 7.15.1 eXmoor Pharma Company Information
  87. 7.15.2 eXmoor Pharma Business Overview
  88. 7.15.3 eXmoor Pharma Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  89. 7.15.4 eXmoor Pharma Gene Cell Therapy CDMO Product Portfolio
  90. 7.15.5 eXmoor Pharma Recent Developments
  91. 7.16 Advanced Therapies
  92. 7.16.1 Advanced Therapies Company Information
  93. 7.16.2 Advanced Therapies Business Overview
  94. 7.16.3 Advanced Therapies Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Advanced Therapies Gene Cell Therapy CDMO Product Portfolio
  96. 7.16.5 Advanced Therapies Recent Developments
  97. 7.17 Catalent Biologics
  98. 7.17.1 Catalent Biologics Company Information
  99. 7.17.2 Catalent Biologics Business Overview
  100. 7.17.3 Catalent Biologics Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Catalent Biologics Gene Cell Therapy CDMO Product Portfolio
  102. 7.17.5 Catalent Biologics Recent Developments
  103. 7.18 Patheon Pharma Services
  104. 7.18.1 Patheon Pharma Services Company Information
  105. 7.18.2 Patheon Pharma Services Business Overview
  106. 7.18.3 Patheon Pharma Services Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Patheon Pharma Services Gene Cell Therapy CDMO Product Portfolio
  108. 7.18.5 Patheon Pharma Services Recent Developments
8 North America
  1. 8.1 North America Gene Cell Therapy CDMO Revenue (2021-2032)
  2. 8.2 North America Gene Cell Therapy CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Gene Cell Therapy CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Gene Cell Therapy CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Gene Cell Therapy CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Gene Cell Therapy CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Gene Cell Therapy CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Gene Cell Therapy CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Gene Cell Therapy CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Gene Cell Therapy CDMO Revenue by Country
  11. 8.6.1 North America Gene Cell Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Gene Cell Therapy CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Gene Cell Therapy CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Gene Cell Therapy CDMO Revenue (2021-2032)
  2. 9.2 Europe Gene Cell Therapy CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Gene Cell Therapy CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Gene Cell Therapy CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Gene Cell Therapy CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Gene Cell Therapy CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Gene Cell Therapy CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Gene Cell Therapy CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Gene Cell Therapy CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Gene Cell Therapy CDMO Revenue by Country
  11. 9.6.1 Europe Gene Cell Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Gene Cell Therapy CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Gene Cell Therapy CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Gene Cell Therapy CDMO Revenue (2021-2032)
  2. 10.2 China Gene Cell Therapy CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Gene Cell Therapy CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Gene Cell Therapy CDMO Revenue by Type (2027-2032)
  5. 10.3 China Gene Cell Therapy CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Gene Cell Therapy CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Gene Cell Therapy CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Gene Cell Therapy CDMO Revenue by Application (2027-2032)
  9. 10.5 China Gene Cell Therapy CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Gene Cell Therapy CDMO Revenue (2021-2032)
  2. 11.2 Asia Gene Cell Therapy CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Gene Cell Therapy CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Gene Cell Therapy CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Gene Cell Therapy CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Gene Cell Therapy CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Gene Cell Therapy CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Gene Cell Therapy CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Gene Cell Therapy CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Gene Cell Therapy CDMO Revenue by Country
  11. 11.6.1 Asia Gene Cell Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Gene Cell Therapy CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Gene Cell Therapy CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Gene Cell Therapy CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Gene Cell Therapy CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Gene Cell Therapy CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Gene Cell Therapy CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Gene Cell Therapy CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Gene Cell Therapy CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Gene Cell Therapy CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Gene Cell Therapy CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Gene Cell Therapy CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Gene Cell Therapy CDMO Revenue by Country
  11. 12.6.1 SAMEA Gene Cell Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Gene Cell Therapy CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Gene Cell Therapy CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst